WPA
TVRD

Wealth Preservation Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Wealth Preservation Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Buy
+8
New +$31 ﹤0.01% 1000

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Wealth Preservation Advisors's TVRD Position: Q1 2026 in Review

Wealth Preservation Advisors opened a new position in Tvardi Therapeutics (TVRD) in Q1 2026: 8 shares worth $25. The stake represents ﹤0.01% of the portfolio and ranks #1000 among its holdings.

67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Wealth Preservation Advisors held 8 shares of Tvardi Therapeutics worth $25 as of Q1 2026.
  • Tvardi Therapeutics was a new Wealth Preservation Advisors position in Q1 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Wealth Preservation Advisors's portfolio in Q1 2026, its #1000 holding.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Wealth Preservation Advisors's 13F filing for Q1 2026, filed 15 May 2026.